Navigation Links
Labopharm Reports Results for First Quarter Fiscal 2009
Date:5/7/2009

,000 of previously recorded write downs while adjusted gross margin for the first quarter of fiscal 2008 excludes an inventory write-off of $152,000 and a favourable adjustment for a royalty expense over-accrual of $105,000. The slight decrease in adjusted gross margin was due primarily to a higher average royalty rate paid, which was partially offset by a higher average selling price per tablet.

Licensing revenue for the first quarter of fiscal 2009 was $1.2 million and represented a portion of licensing payments received from the Company's licensing and distribution partners for once-daily tramadol. Licensing revenue for the first quarter of fiscal 2008 was $1.1 million.

Research and development expenses, before research and development tax credits, for the first quarter of fiscal 2009 were $4.3 million compared with $6.9 million for the first quarter of fiscal 2008. The decrease was primarily the result of lower clinical trial costs in the first quarter of fiscal 2009. Research and development tax credits for the first quarter of fiscal 2009 were $0.3 million compared with $1.2 million for the first quarter of fiscal 2008, a decrease in non-refundable Canadian federal tax credits resulting from a change in tax planning.

Selling, general and administrative expenses for the first quarter of fiscal 2009 were $6.7 million compared with $4.9 million for the first quarter of fiscal 2008. The increase is primarily the result of the accrual of $0.7 million for the Company's share of litigation costs incurred by Purdue Pharma to enforce certain of Purdue's U.S. patents related to Labopharm's once-daily tramadol product, as well as higher sales and marketing expenses.

Net loss for the first quarter of fiscal 2009 was $8.0 million, or $0.14 per share, compared with $9.7 million, or $0.17 per share, for the first quarter of fiscal 2008.

Cash, cash equivalents and marketable securities at March 31, 2009 were $35.9 million com
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Mozes HealthDay Reporter ... burdened by stress and family conflicts before surgery may ... a new study suggests. Investigators found that patients ... nearly three times greater risk for complications compared to ... "We,ve long known that patient quality of life ...
(Date:9/19/2014)... cells to treat and cure disease is a ... hindered by the inability of doctors and scientists to ... cells in patients without resorting to invasive procedures, like ... in the online journal Magnetic Resonance in Medicine ... School of Medicine, University of Pittsburgh and elsewhere describe ...
(Date:9/19/2014)... CHICAGO --- Domestic violence occurs at least as ... couples compared to opposite-sex couples, according to a ... , Previous studies, when analyzed together, indicate ... percent of lesbian, gay and bisexual individuals. However, ... abuse paints an incomplete picture of the true ...
(Date:9/19/2014)... NY (PRWEB) September 20, 2014 As summer ... Krishnan DMD in Queens, NY now reminds area patients about ... than 80% of our population affected by gum disease, there ... longer.” , For over 20 years Dr. Krishnan has treated ... Hills office location. “Most patients that come in due to ...
(Date:9/19/2014)... 19, 2014) Shahram Majidi, M.D., a second-year ... George Washington University School of Medicine and Health ... Heart Association to study the presence of diffuse ... hemorrhage (ICH). , "According to epidemiological studies, intracerebral ... all strokes, but is the least treatable form ...
Breaking Medicine News(10 mins):Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:A better way to track emerging cell therapies using MRIs 2Health News:Domestic violence likely more frequent for same-sex couples 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:GW researcher receives grant to study brain swelling following bleeding in the brain 2
... Indonesia's resort island of Bali, health officials have culled ... to Bali from the adjacent Java Island, reported Anak ... than 24 bird flu related deaths have been reported ... to the above situation, import of poultry and livestock ...
... by Dr. Martina Stippler it was found that magnesium levels ... A team at the University Of Pittsburgh Brain Trauma Research ... severe brain injuries. The study results were presented at the ... San Francisco. ,The results show that 35 of ...
... demanding the government for new and better breast cancer drugs. ... for Clinical Excellence rejected two new breast cancer drugs for ... groups who were campaigning for access to every new drug ... in clinical trials. The two drugs were docetaxel and paclitaxel. ...
... County Hospital (RHCH) in Winchester, which is already suffering from ... spending ?359,000 caring// for two patients even though they do ... hospital for two years even though they do not need ... since April 2004, the so called "bed blockers", have not ...
... defended the hike in salaries offered to GPs after negative ... claiming //that the wage hikes were responsible for NHS deficits. ... and since then salaries have increased by 25 percent. BMA's ... sensational headlines over the pay being as much as ?100,000 ...
... the cancers that results in death among the Britons. ... a tablet// called Xeloda have only been given to ... Institute of Health and Clinical Excellence (NICE) issued guidance ... who had cancerous tissue removed at an early stage. ...
Cached Medicine News:Health News:Hospitals Facing Huge Losses From Healthy Patients Yet To Discharge 2
(Date:9/19/2014)... 2014 Research and Markets has announced ... Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023" ... of this report, the human microbiome market is segmented by ... market is expected to be valued as $294 million in ... 22.3% within the forecast period of 2019-2023. The market is ...
(Date:9/19/2014)... Sept. 19, 2014 UBM Medica US announces ... online community to help oncologists and other clinicians gain ... the use of targeted therapies and immunotherapies, discusses some ... treatment.  Every September, Blood Cancer ... raise awareness about blood cancers—helping to increase survival rates ...
(Date:9/19/2014)... Sept. 19, 2014  Alere Inc. (NYSE: ... the following statement today in support of President ... "As the global leader in rapid diagnostics for ... national strategy to address the serious threat of antibiotic ... the Administration on initiatives to promote the development of ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... LAIYANG, China , May 17 /PRNewswire-Asia-FirstCall/ -- ... pharmaceutical company with its principal operations in the People,s,Republic ... quarter,fiscal year 2010 ended March 31, 2010 . , ... -- Revenue was $25.6 million, a slight decrease of 0.6% ...
... Connecticut waterways may be safer from biomedical waste, thanks to ... CEDF, with loan-program partners, Connecticut ,s Department of Economic and Community and ... to a West Haven company that stems improper disposal of needles ... West Haven ...
Cached Medicine Technology:Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 2Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 3Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 4Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 5Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 6Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 7Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 8Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 9Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 10Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 11Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 12Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 13Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 14Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 15Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 16Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 17Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 18Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 19Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 20Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 21West Haven Firm Expands Biomedical Disposal Program with Community Economic Development Fund 2
...
...
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
Monitorr ICP external CSF drainage system with self-contained ICP setting....
Medicine Products: